Skip to main content
. 2020 Aug 30;41(38):3702–3710. doi: 10.1093/eurheartj/ehaa651

Figure 3.

Figure 3

Kaplan–Meier curves showing safety and efficacy endpoints in the BAMI trial. (A) Cumulative incidence functions for any adverse event up to 6 months (safety set). (B) Cumulative incidence functions for serious adverse events up to 5 years (trial end) (safety set). (C) Cumulative incidence functions for re-hospitalization due to stroke up to 5 years (trial end) (safety set). (D) Cumulative incidence functions for bleeding up to 5 years (trial end) (safety set).